Abstract:The coronavirus disease 2019 pandemic has caused more than 532 million infections and 6.3 million deaths to date. The reactive and neutralizing fully human antibodies of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective detection tools and therapeutic measures. During SARS-CoV-2 infection, a large number of SARS-CoV-2 reactive and neutralizing antibodies will be produced. Most SARS-CoV-2 reactive and neutralizing fully human antibodies are isolated from human and frequently encoded by convergent heavy-chain variable genes. However, SARS-CoV-2 viruses can mutate rapidly during replication and the resistant variants of neutralizing antibodies easily survive and evade the immune response, especially in the face of such focused antibody responses in humans. Therefore, additional tools are needed to develop different kinds of fully human antibodies to compensate for current deficiency. In this study, we utilized antibody humanized CAMouse HG mice to develop a rapid antibody discovery method and examine the antibody repertoire of SARS-CoV-2 RBD-reactive hybridoma cells derived from CAMouse HG mice by using high-throughput single-cell V(D)J sequencing analysis. CAMouse HG mice were immunized by 28-day rapid immunization method. After electrofusion and semi-solid medium screening on day 12 post-electrofusion, 171 hybridoma clones were generated based on the results of SARS-CoV-2 RBD binding activity assay. A rather obvious preferential usage of IGHV6-1 family was found in these hybridoma clones derived from CAMouse HG mice, which was significantly different from the antibodies found in patients with COVID-19. After further virus neutralization screening and antibody competition assays, we generated a noncompeting two-antibody cocktail, which showed a potent prophylactic protective efficacy against SARS-CoV-2 in cynomolgus macaques. These results indicate that humanized CAMouse HG mice not only provide a valuable platform to obtain fully human reactive and neutralizing antibodies but also have a different antibody repertoire from humans. Thus, humanized CAMouse HG mice can be used as a good complementary tool in discovery of fully human therapeutic and diagnostic antibodies.

Production of an Anti-Severe Acute Respiratory Syndrome (SARS) Coronavirus Human Monoclonal Antibody Fab Fragment by Using a Combinatorial Immunoglobulin Gene Library Derived from Patients Who Recovered from SARS.

A human neutralizing antibody against a conforma- tional epitope shared by oligomeric SARS S1 protein

Isolation and Identification of an Scfv Antibody Against Nucleocapsid Protein of SARS-CoV.

Neutralizing Antibodies to SARS‐CoV‐2 Selected from a Human Antibody Library Constructed Decades Ago

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

A human SARS-CoV neutralizing antibody against epitope on S2 protein.

Human IgG Neutralizing Monoclonal Antibodies Block SARS-CoV-2 Infection

Production of a monoclonal antibody against SARS-CoV spike protein with single intrasplenic immunization of plasmid DNA

Potent Cross-Reactive Neutralization of SARS Coronavirus Isolates by Human Monoclonal Antibodies.

Specific anti-SARS-CoV-2 S1 IgY-scFv is a promising tool for recognition of the virus

Cloning, Expression, Purification of a Fusion Protein of SARS-CoV Nucleocapsid and Spike Protein Fragments and Its Immunological Characteristics

Fully Human Single-Domain Antibodies Against SARS-CoV-2

A SARS-CoV-2 neutralizing antibody with exceptional spike binding coverage and optimized therapeutic potentials

Potent human neutralizing antibodies elicited by SARS-CoV-2 infection

Cross-neutralization Antibodies Against SARS-CoV-2 and RBD Mutations from Convalescent Patient Antibody Libraries

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

Conserved Amino Acids W423 and N424 in Receptor-Binding Domain of SARS-CoV Are Potential Targets for Therapeutic Monoclonal Antibody.

Use of Viral Lysate Antigen Combined with Recombinant Protein in Western Immunoblot Assay As Confirmatory Test for Serodiagnosis of Severe Acute Respiratory Syndrome

Discovery and characterization of SARS-CoV-2 reactive and neutralizing antibodies from humanized CAMouseHG mice through rapid hybridoma screening and high-throughput single-cell V(D)J sequencing

Development and Evaluation of an Enzyme-Linked Immunosorbent Assay for Detection of Antibodies Against the Spike Protein of Sars-Coronavirus